TH-4000: Phase I/II data

An open-label, dose-escalation, international Phase I/II trial in 27 patients with solid tumors showed that the MTD of IV TH-4000 was once-weekly 150 mg/m 2. At 200 mg/m 2 TH-4000, 2 patients experien...